Overview: Chimerism Pre-Engraftment Donor Recipient Panel
Introduction: The Chimerism Pre-Engraftment Donor Recipient Panel is a diagnostic tool designed to assess donor-recipient compatibility using whole blood samples. In India, pre-transplant chimerism profiling establishes distinct DNA profiles for accurate post-HSCT monitoring in allogeneic transplants. High burden of hematological disorders requiring HSCT, with baseline donor/recipient DNA essential for detecting engraftment. High morbidity from inadequate pre-testing in resource-limited centers leading to post-transplant misinterpretation. Per hematology practices aligned with ICMR guidelines, the test employs PCR for donor/recipient DNA profile analysis over 1-2 days with high accuracy, valuable for establishing reference. This diagnostic falls under pre-transplant evaluation and targets HSCT donor-recipient pairs, addressing accurate compatibility baseline to guide monitoring. With elevated risks due to under-testing, the test supports public health efforts by enabling precise engraftment tracking. Its whole blood-based approach ensures reliable detection.
Other Names: Chimerism D/R Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology/hematology, compliant with 2025 standards.
Historical Milestone: Pre-transplant profiling standard; in India, essential in transplant protocols.
Purpose: The test assesses 2 parameters including donor DNA profile to guide pre-engraftment compatibility, establish baseline, inform post-transplant monitoring.
Test Parameters: 1. Donor DNA Profile, 2. Recipient DNA Profile.
Pretest Condition: No fasting required; patients should be pre-HSCT donor-recipient pairs.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Patients should provide details on transplant indication, donor match, prior transfusions.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of inaccurate baseline including misinterpretation, benefits of pre-testing, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Distinct donor/recipient profiles established for post-transplant comparison, necessitating specialist input.
Specialist Consultation: Transplant hematologists should be consulted for interpretation.
Additional Supporting Tests: HLA typing for confirmation.
Test Limitations: Pre-transplant only; comprehensive approach required.
References: Indian Journal of Hematology 2024, HSCT Studies India 2023.
